N-(3-methoxy-4-methylphenyl)-2,2-dimethylpropanamide | 143096-34-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(3-methoxy-4-methylphenyl)-2,2-dimethylpropanamide
• 英文别名: N-(3-methoxy-4-methylphenyl)pivalamide；3-Methoxy-4-methyl-N-pivaloylaniline
• CAS: 143096-34-8
• 化学式: C₁₃H₁₉NO₂
• 分子量: 221.299
• InChiKey: QIZAQTFZWUFZFC-UHFFFAOYSA-N

物化性质

• 沸点：
  360.4±30.0 °C(Predicted)
• 密度：
  1.042±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-(3-methoxy-4-methylphenyl)-2,2-dimethylpropanamide 在 吡啶 、 potassium permanganate 、 正丁基锂 、 三乙胺 作用下， 以 四氢呋喃 、 正己烷 、 水 为溶剂， 反应 15.0h， 生成 2-methoxy-3-(methylcarbamoyl)-4-pivalamidobenzoicacid
  参考文献：
  名称：

  Design, synthesis and antiviral activity of novel quinazolinones

  摘要：

  HIV-1 integrase (IN) is a validated therapeutic target for antiviral drug design. However, the emergence of viral strains resistant to clinically studied IN inhibitors demands the discovery of novel inhibitors that are structurally as well as mechanistically different. Herein, a series of quinazolinones were designed and synthesized as novel HIV-1 inhibitors. The new synthetic route provides a practical method for the preparation of 5-hydroxy quinazolinones. Primary bioassay results indicated that most of the quinazolinones possess anti-HIV activity, especially for compound 11b with 77.5% inhibition rate at 10 mu M emerged as a new active lead. Most of the synthesized compounds were also found to exhibit good anti-TMV activity, of which compound 9a showed similar in vivo anti-TMV activity to commercial plant virucide Ribavirin. This work provides a new and efficient approach to evolve novel multi-functional antiviral agents by rational integration and optimization of previously reported antiviral agents. (C) 2012 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2012.04.010
• 作为产物：
  描述：

  5-氨基-2-甲基苯酚 在 sodium carbonate 、 potassium carbonate 作用下， 以 水 、 乙酸乙酯 、 N,N-二甲基甲酰胺 为溶剂， 反应 5.0h， 生成 N-(3-methoxy-4-methylphenyl)-2,2-dimethylpropanamide
  参考文献：
  名称：

  收敛的方法二苯并二恶英酮：外消旋青霉素的合成

  摘要：

  探索了一种收敛的方法，即基于5-氨基-2-甲基苯酚（5），可以13步获得外消旋青霉素（（±）-1a），总产率为4.2％（方案2-4）。

  DOI：

  10.1002/hlca.201100405

文献信息

• Substituted dibenz-oxa-thiocinones, -12-oxides and -12,12-dioxides, a
  申请人：Bayer Aktiengesellschaft

  公开号：US05190971A1

  公开（公告）日：1993-03-02

  The invention relates to substituted dibenz-oxa-thiocinone-12-oxides and -12,12-dioxides of the general formula I ##STR1## in which R.sup.1 to R.sup.6 and Y have the meaning indicated in the description, to processes for their preparation and to their use in medicaments, in particular in circulation-influencing medicaments.

  该发明涉及一般式I的取代二苯基氧硫代环己酮-12-氧化物和-12,12-二氧化物，其中R.sup.1至R.sup.6和Y具有描述中所示的含义，以及它们的制备过程和在药物中的使用，特别是在影响循环的药物中的使用。
• 5-QUINOLINONE DERIVATIVES AS 5HT1A RECEPTOR MODULATORS FOR TREATING SEXUAL DYSFUNCTION, COGNITION IMPAIRMENT, PSYCHOTIC DISORDERS, ANXIETY, DEPRESSION, ETC.
  申请人：Bertani Barbara

  公开号：US20100004452A1

  公开（公告）日：2010-01-07

  Disclosed are compounds of formula (I) wherein R 1 is C 1-6 alkyl, halo or haloC 1-6 alkyl; R 2 is hydrogen or C 1-6 alkyl; is a single or double bond; each R 3 and R 4 , which may be the same or different, are hydrogen, C 1-6 alkyl or haloC 1-6 alkyl; wherein i) when is a double bond p and q are 1, and ii) when is a single bond, p and q are 2, and one of R 3 and one of R 4 , together with their interconnecting atoms, forms a cyclopropane ring which may be substituted by one or two halo or methyl groups, which groups may be the same or different; X is CH or N; when present each R 5 , which may be the same or different, is C 1-6 alkyl or halo; or two R 5 groups may join to form a bridge, which bridge contains one or two atoms; n is 0, 1, 2 or 3; when present each R 6 which may be the same or different, is C 1-6 alkyl or halo; and m is 0, 1, 2 or 3.

  本发明涉及式（I）的化合物，其中R1为C1-6烷基，卤素或卤素C1-6烷基；R2为氢或C1-6烷基；为单键或双键；每个R3和R4，可以相同也可以不同，为氢，C1-6烷基或卤素C1-6烷基；其中i）当为双键时，p和q为1，ii）当为单键时，p和q为2，其中R3和R4中的一个以及它们的连接原子组成一个环丙烷环，该环可以被一个或两个卤素或甲基基团取代，这些基团可以相同也可以不同；X为CH或N；当存在时，每个R5可以相同也可以不同，为C1-6烷基或卤素；或两个R5基团可以结合形成一个桥，该桥包含一个或两个原子；n为0、1、2或3；当存在时，每个R6可以相同也可以不同，为C1-6烷基或卤素；m为0、1、2或3。
• Substituierte Dibenz-oxa-thiocinone, -12-oxide und -12,12-dioxide, Verfahren zu ihrer Herstellung und ihre Verwendung in Arzneimitteln
  申请人：BAYER AG

  公开号：EP0490219A1

  公开（公告）日：1992-06-17

  Die Erfindung betrifft substituierte Dibenz-oxa-thiocinon-12-oxide und -12,12-dioxide der allgemeinen Formel I in welcher R¹ bis R⁶ und Y die in der Beschreibung angegebene Bedeutung haben, Verfahren zu ihrer Herstellung und ihre Verwendung in Arzneimitteln, insbesondere in kreislaufbeeinflussenden Arzneimitteln.

  本发明涉及通式 I 的取代二苯并氧噻嗪酮-12-氧化物和-12,12-二氧化物 中 R¹ 至 R⁶ 和 Y 的含义，以及它们的制备工艺和在药物中的用途，特别是在影响循环的药物中的用途。
• US5190971A
  申请人：——

  公开号：US5190971A

  公开（公告）日：1993-03-02
• Design, synthesis and antiviral activity of novel quinazolinones
  作者：Ziwen Wang、Mingxiao Wang、Xue Yao、Yue Li、Juan Tan、Lizhong Wang、Wentao Qiao、Yunqi Geng、Yuxiu Liu、Qingmin Wang

  DOI：10.1016/j.ejmech.2012.04.010

  日期：2012.7

  HIV-1 integrase (IN) is a validated therapeutic target for antiviral drug design. However, the emergence of viral strains resistant to clinically studied IN inhibitors demands the discovery of novel inhibitors that are structurally as well as mechanistically different. Herein, a series of quinazolinones were designed and synthesized as novel HIV-1 inhibitors. The new synthetic route provides a practical method for the preparation of 5-hydroxy quinazolinones. Primary bioassay results indicated that most of the quinazolinones possess anti-HIV activity, especially for compound 11b with 77.5% inhibition rate at 10 mu M emerged as a new active lead. Most of the synthesized compounds were also found to exhibit good anti-TMV activity, of which compound 9a showed similar in vivo anti-TMV activity to commercial plant virucide Ribavirin. This work provides a new and efficient approach to evolve novel multi-functional antiviral agents by rational integration and optimization of previously reported antiviral agents. (C) 2012 Elsevier Masson SAS. All rights reserved.